Signaling mechanisms in neuroendocrine tumors as targets for therapy

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 4, 2010, Pages 801-810

  Zarebczan, Barbara ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Carcinoid; Medullary thyroid cancer; Neuroendocrine tumor; Signaling pathways

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ETOPOSIDE; EVEROLIMUS; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE INHIBITOR; LEFLUNOMIDE; LITHIUM CHLORIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN AKT3; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; SUBEROYL DIHYDROXAMIC ACID; TAUTOMYCIN; TEMSIROLIMUS; TERIFLUNOMIDE; TRANSCRIPTION FACTOR MASH1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANDETANIB; WORTMANNIN;

AMINO TERMINAL SEQUENCE; BIPOLAR DISORDER; CARCINOID; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FAMILIAL CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ANIMALS; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; THYROID NEOPLASMS;

EID: 78649347942     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.08.002     Document Type: Review

References (59)

1. Kim T., Grobmyer S., Liu C., et al. Primary presacral neuroendocrine tumor associated with imperforate anus. World J Surg Oncol 2007, 5:115.
2. Luo J., Manning B., Cantley L. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4(4):257-262.
3. Vivanco I., Sawyers C. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501.
4. Krystal G., Sulanke G., Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002, 1(11):913-922.
5. Pitt S., Chen H., Kunnimalaiyaan M. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol 2009, 16(10):2936-2942.
6. Murtaugh L., Stanger B., Kwan K., et al. Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci U S A 2003, 100(25):14920-14925.
7. Kadesch T. Notch signaling: the demise of elegant simplicity. Curr Opin Genet Dev 2004, 14(5):506-512.
8. Radtke F., Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat Rev Cancer 2003, 3(10):756-767.
9. Kunnimalaiyaan M., Traeger K., Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005, 289(4):G636-G642.
10. Nakakura E., Sriuranpong V., Kunnimalaiyaan M., et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by Notch signaling. J Clin Endocrinol Metab 2005, 90(7):4350-4356.
11. Sippel R., Carpenter J., Kunnimalaiyaan M., et al. The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery 2003, 134(6):866-871. [discussion: 871-3].
12. Kunnimalaiyaan M., Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?. Anticancer Drugs 2006, 17(2):139-142.
13. Greco A., Borrello M., Miranda C., et al. Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009, 53(5):440-453.
14. Walker G., Hayward N. Pathways to melanoma development: lessons from the mouse. J Invest Dermatol 2002, 119(4):783-792.
15. Zarebczan B., Chen H. Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir 2010, 65(1):59-69.
16. Pitt S., Chen H., Kunnimalaiyaan M. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg 2009, 209(1):82-88.
17. Wang L., Ignat A., Axiotis C. Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002, 10(2):139-146.
18. Shah T., Hochhauser D., Frow R., et al. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol 2006, 18(5):355-360.
19. Forgacs E., Biesterveld E., Sekido Y., et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998, 17(12):1557-1565.
20. Yokomizo A., Tindall D., Drabkin H., et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998, 17(4):475-479.
21. Moreno A., Akcakanat A., Munsell M., et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008, 15(1):257-266.
22. Duran I., Kortmansky J., Singh D., et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95(9):1148-1154.
23. Yao J., Phan A., Chang D., et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26(26):4311-4318.
24. Hardt S., Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 2002, 90(10):1055-1063.
25. Cohen P., Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001, 2(10):769-776.
26. Kunnimalaiyaan M., Vaccaro A., Ndiaye M., et al. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007, 6(3):1151-1158.
27. Cook M., Yu X., Chen H. Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am J Transl Res 2010, 2(1):119-125.
28. Kunnimalaiyaan M., Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 2007, 12(5):535-542.
29. Allenspach E., Maillard I., Aster J., et al. Notch signaling in cancer. Cancer Biol Ther 2002, 1(5):466-476.
30. Ito T., Udaka N., Yazawa T., et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 2000, 127(18):3913-3921.
31. Lanigan T., DeRaad S., Russo A. Requirement of the MASH-1 transcription factor for neuroendocrine differentiation of thyroid C cells. J Neurobiol 1998, 34(2):126-134.
32. Ellisen L., Bird J., West D., et al. TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66(4):649-661.
33. Sriuranpong V., Borges M., Ravi R., et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001, 61(7):3200-3205.
34. Kunnimalaiyaan M., Vaccaro A., Ndiaye M., et al. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006, 281(52):39819-39830.
35. Stockhausen M., Sjölund J., Manetopoulos C., et al. Effects of the histone deacetylase inhibitor valproic acid on notch signalling in human neuroblastoma cells. Br J Cancer 2005, 92(4):751-759.
36. Greenblatt D., Vaccaro A., Jaskula-Sztul R., et al. Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007, 12(8):942-951.
37. Ning L., Greenblatt D., Kunnimalaiyaan M., et al. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist 2008, 13(2):98-104.
38. Chen H., Kunnimalaiyaan M., Van Gompel J. Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid 2005, 15(6):511-521.
39. Dhillon A., Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 2004, 5(4):303-304.
40. Younes N., Fulton N., Tanaka R., et al. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 1997, 79(9):1804-1808.
41. Ravi R., Thiagalingam A., Weber E., et al. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. Am J Respir Cell Mol Biol 1999, 20(4):543-549.
42. Ravi R., Weber E., McMahon M., et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998, 101(1):153-159.
43. Sippel R., Carpenter J., Kunnimalaiyaan M., et al. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2003, 285(2):G245-G254.
44. Sippel R., Chen H. Activation of the ras/raf-1 signal transduction pathway in carcinoid tumor cells results in morphologic transdifferentiation. Surgery 2002, 132(6):1035-1039. [discussion: 1039].
45. Park J., Strock C., Ball D., et al. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 2003, 23(2):543-554.
46. Hall-Jackson C., Eyers P., Cohen P., et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999, 6(8):559-568.
47. Van Gompel J., Kunnimalaiyaan M., Holen K., et al. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005, 4(6):910-917.
48. Pinchot S., Adler J., Luo Y., et al. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009, 197(3):313-319.
49. ClinicalTrials.gov. Available at:, Accessed April 20, 2010. http://clinicaltrials.gov/ct2/show/NCT00602082%3Fterm%3Dstreptozocin%26rank%3D2.
50. Cook M., Pinchot S., Jaskula-Sztul R., et al. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther 2010, 9(2):429-437.
51. Cakir M., Grossman A. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009, 90(4):323-348.
52. de Groot J., Links T., Plukker J., et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006, 27(5):535-560.
53. Segouffin-Cariou C., Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000, 275(5):3568-3576.
54. Santoro M., Melillo R., Carlomagno F., et al. Molecular biology of the MEN2 gene. J Intern Med 1998, 243(6):505-508.
55. Herbst R., Heymach J., O'Reilly M., et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007, 16(2):239-249.
56. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62(24):7284-7290.
57. Sherman S. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008, 37(2):511-524.
58. Kulke M., Scherübl H. Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2009, 3(5 Suppl 2):S62-S66.
59. Dimou A., Syrigos K., Saif M. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium" Orlando, FL, USA. January 22-24, 2010. JOP 2010, 11(2):135-138.